BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration 4
59 Several clinical trials are underway to evaluate the use of GLP-1 medicines for reducing alcohol intake in patients with AUD (NCT06015893, NCT05891587, and NCT05892432) and AUD with comorbid obesity (NCT05895643)
In 2019, bremelanotide received FDA approval as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, marking a significant milestone as one of the first centrally-acting agents approved for female sexual dysfunction
The generalizability of these results to real-world clinical practice remains uncertain
The Ozempic vs retatrutide guide covers the practical comparison including approval status, availability, and cost differences
Palmitoylation of gephyrin controls receptor clustering and plasticity of GABAergic synapses
